Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
Leukemia & lymphoma | 2013-12-01 | PMID 23547837
Jones Jeffrey A, Ruppert Amy S, Zhao Weiqiang and 7 more
